Navigation Links
EPSScentral Responds to Pandemic Alert
Date:5/4/2009

ANNANDALE, Va., May 4 /PRNewswire/ -- EPSScentral LLC today announced its readiness to assist organizations in assembling, communicating, and implementing mitigation measures in the face of WHO's phase 5 classification of the Influenza A crisis. According to the WHO, phase 5 "...is a strong signal that a pandemic is imminent and that the time to finalize... mitigation measures is short."

(Logo: http://www.newscom.com/cgi-bin/prnh/20080701/DC26612LOGO)

A world leader in ensuring organizational competency and performance, EPSScentral, together with pandemic content experts and technology partners, developed a package to address pandemic planning needs. Commencing with the SARS and Avian Flu crises over the past two years, EPSScentral developed the solution as a component of its process improvement and standard operating procedures practices. According to President and CEO Gary J. Dickelman, "It is socially responsible at this time to communicate our rapid, innovative approach to mitigating business disruption caused by Influenza A, especially in these challenging economic times. Having a solid plan in place mitigates overreacting to pandemic press. It prevents unnecessary business disruption while addressing the health and safety of employees in measured and responsible ways."

EPSScentral's offering includes: A baseline, easily customizable pandemic contingency plan; a set of templates and tools for rapid localization and deployment; resources to jump-start customization; and access to additional expert knowledge as the Influenza A (aka H1N1, Swine Flu) or other pandemic scenarios evolve. A sample EPSScentral pandemic plan can be viewed at '/>"/>

SOURCE EPSScentral LLC
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
2. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
3. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
4. Roche responds to announcement of IDEAL hepatitis C trial results
5. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
6. USAID Cooperates in Pandemic Preparedness Initiative
7. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
8. Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
9. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
10. Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
11. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...Newswire-FirstCall/ -- MedQuist Inc. (Nasdaq: MED...ical documentation services, today announced that ...ons, Inc. (Nuance) under which MedQuist will now l...ine and processing software for use in SpeechQ of ...recognition application for all medical discipline...
(Date:11/30/2009)...ewswire/ -- Reportlinker.com announces that a new ...ue: ,, Diabetes Diagnostics - A Global Market ...164347/Diabetes-Diagnostics---A-Global-Market-Pers...driven by a steady increase in the number of peopl...nd developing parts of the world, and increase in ...
(Date:11/30/2009)...-- Dr. Jocelyn Rapelyea, Associate Director of Bre...University Medical Center in Washington, D.C., dem...t-Specific Gamma Imaging (BSGI) can be localized u...as well, as for pre-operative localization today a...f North America (RSNA). ,, BSGI was conducted u...
Breaking Medicine Technology:MedQuist Signs Agreement Extending Use of Real-Time Speech Recognition Engine to Wide Range of Medical Specialties 2Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 2Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 3Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 4Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 5Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 6Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 7Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 8Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 9Breast-Specific Gamma Imaging Identifies Occult Lesions Using Multi-Modality Imaging for Biopsy 2Breast Cancer Numbers Dip Most in Wealthy Urban Areas 50200 1Breast Cancer Numbers Dip Most in Wealthy Urban Areas 50200 2The Psychology of Celebrity Worship 50198 1The Psychology of Celebrity Worship 50198 2The Psychology of Celebrity Worship 50198 3Discus Dental Files Suit to Protect BriteSmile 28R 29 Trademark 50197 1Discus Dental Files Suit to Protect BriteSmile 28R 29 Trademark 50197 2
...June 4 AstraZeneca (NYSE:,AZN) today announced th...n,(sNDA) to the U.S. Food and Drug Administration ...RT(R) (budesonide/formoterol fumarate dihydrate),I...eatment of asthma in,pediatric patients ages 6 to ...the long-term maintenance treatment of asthma in p...
... 4 Semafore Pharmaceuticals Inc.,today reported i...ct,candidate, SF1126, a targeted pan-PI3 kinase (P...mors. SF1126 is the first PI3 kinase inhibitor to ...ltiple myeloma trials., The data from the solid t...ed in a twice-weekly I.V. infusion at exposure lev...
Other Medicine Technology:AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 2AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 3AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 4AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 5AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 6Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors 2Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors 3
(Date:11/30/2009)..., , DEL MAR, Calif., Nov. 30 /PRNewswire...ration (Pink Sheets: ADHC) is pleased to announce ...dependent director to the Company,s Board of Direc...s over a 40 year period starting at the Chemical B...artner of Harris, Bretall & McEldowney, San Fr...
(Date:11/30/2009)..., , PHILADELPH...l/ -- , - Exclusive Updates From Elsevier...re Reform and ARRA Momentum , Elsevier, a...on as well,as web-based and electronic health reco...ew online resource center for American Recovery an...
(Date:11/30/2009)... The U.S. Centers for Disease Control and Preventi...he United States are infected with HIV/AIDS. New r... that many of those infected are minorities and do...d for a national strategy to facilitate education ...populations. , The research, which analyzed 90,0...
(Date:11/30/2009)... The University of Navarra Hospital has launched a...efficacy of an immunotherapy treatment. This appro...nes produced from healthy and tumour cells from th...ioblastomas, one of the most aggressive and freque...red to participating patients combined with the st...
(Date:11/30/2009)...lder alcoholics tend to drink heavily more often t...NDAY, Nov. 30 (HealthDay News) -- Older people who...eir younger counterparts, a new report finds, poss... same effect. , According to a study released ...der than 60 consume more than 40 drinks a week, on...
Breaking Medicine News(10 mins):Health News:American Diversified Holdings Corporation Announces Appointment of Independent Director to the Board of the Company 2Health News:Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog 2Health News:Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog 3Health News:Elsevier Launches New Online ARRA Resource Center and Clinical Decision Support Blog 4Health News:Research highlights need for national HIV strategy 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 3Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 4Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 5Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 6Health News:Binge Drinking Not Just a Rite of the Young 2
...P(R),s charitable Sight for Students(R) program an...ception in 1997. The program has funded almost $10...me, uninsured and underinsured children. , , (P...ce, the nation,s largest partnership network worki...
... Treatments , , OTTAWA, March 9 /PRNewswire-First... isotopes and radiopharmaceuticals, today announce...for TheraSphere(R), Yttrium-90 Microsphere (Y-90),...er, faster, and more efficient administration of T...
...d expect to need reading glasses or bifocals durin...ed presbyopia. LASIK, a proven technique for freed...r presbyopia. , , But today, according to result...mpletely eliminated the need for all glasses for 9...
...mex: HH ) today announced that it will release f...before market on Friday, March 13, 2009. The Comp...3, 2009 at 11:00am Eastern Time. , , Conferen...n the Company,s web site located at www.hooperhol...
...f Cosmetic Scientists Meeting , , PROVO, Utah, Ma...nternal free radical generator, age-related NOX (a...ses, Inc. (NYSE: NUS ) links the enzyme to age-r... of Cosmetic Scientists (ASCS), March 2-4, in Yoko...
...Take a Second Look at Patent in a Reexamination Pr... Community , , NEW YORK, March 9 Article One Par...he validity of Merck & Co.,s SINGULAIR U.S. dr...an independent expert join Article One,s opinion t...
Other Medicine News:Health News:VSP's Sight for Students Program Helps 500,000th Child 2Health News:VSP's Sight for Students Program Helps 500,000th Child 3Health News:MDS Nordion Launches Improved TheraSphere(R) Administration System for Physicians 2Health News:MDS Nordion Launches Improved TheraSphere(R) Administration System for Physicians 3Health News:Hooper Holmes Announces Fourth Quarter Earnings Release Date and Conference Call Information 2Health News:Study Links Internal Source of Aging and Skin Damage 2Health News:Study Links Internal Source of Aging and Skin Damage 3Health News:Article One Partners Uncovers New Prior Art Impacting the Validity of Merck's SINGULAIR Patent 2Health News:Article One Partners Uncovers New Prior Art Impacting the Validity of Merck's SINGULAIR Patent 3Health News:Article One Partners Uncovers New Prior Art Impacting the Validity of Merck's SINGULAIR Patent 4
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
Medicine Products: